Latest News

When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...

Spire Global (SPIR) recently became profitable, with its net profit margin turning positive over the past year. Despite crossing into the black, earnings are forecast to decline sharply at an annual rate of 70% over the next three years, even as revenue is projected to grow just 2.5% per year, lagging far behind the US market average of 10.5%. For investors, this means the company is coming off a milestone of positive earnings, but expectations remain muted due to forecasts for falling...

Core Molding Technologies (CMT) is aiming for a massive 46.5% annual EPS growth rate over the next three years, which easily outpaces the US market average of 16%. This outlook comes as the company posts a forecasted 6.4% revenue growth per year, lagging the US market’s 10.5% average, and a net profit margin of 3.1%, down from 4.9% a year ago. After growing earnings at 20.7% per year over the last five years, CMT enters this period with a high-quality earnings track record but faces margin...

Key Insights P.E. Analytics' estimated fair value is ₹139 based on 2 Stage Free Cash Flow to Equity P.E. Analytics...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Banco Products (India) (NSE:BANCOINDIA) has had a great run on the share market with its stock up by a significant 35...

Taysha Gene Therapies (TSHA) remains unprofitable, but its revenue is forecast to grow rapidly by 70.5% per year, far outpacing the broader US market's expected 10.5% annual growth. Over the past five years, the company has managed to cut its losses at a 7.5% annual rate, even as it is projected to stay in the red for at least the next three years. With shares recently trading at $4.27, below an estimated fair value of $20.71, investors are weighing the promise of significant top-line growth...

Navin Fluorine International Limited ( NSE:NAVINFLUOR ) has announced that it will pay a dividend of ₹6.50 per share on...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Portillo’s (PTLO) is forecast to grow revenue at 8.5% per year, which trails the broader US market’s pace of 10.5%. Despite this, the company’s earnings are expected to climb 16.9% per year, a notch above the market’s 16% average, while net profit margins edged down to 3.4% from last year’s 3.6%. Investors are watching this mix of slower sales growth but faster earnings momentum, especially as the company maintains modest profitability and a valuation that sits between direct peers and the...

Kundan Edifice Limited ( NSE:KEL ) shareholders would be excited to see that the share price has had a great month...

Leidos Holdings (LDOS) posted 16.9% earnings growth for the past year, outpacing its five-year average of 13.7% per year. Net profit margin also improved to 8.1% from last year’s 7.4%, while management continues to deliver high-quality results. Looking ahead, consensus expects earnings to increase by 3.5% per year and revenue by 2.7%, both trailing the broader U.S. market averages. See our full analysis for Leidos Holdings. Next, we will see how these headline numbers compare to the current...

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...

Castle Biosciences (CSTL) continues to operate at a loss, with recent filings confirming the company has yet to achieve net profit margin improvement over the past year and is still generating negative earnings. Despite reducing its annual losses at a rate of 9.6% per year over the last five years, it remains on a slower growth path. Forecasted revenue is expected to rise 6.5% per year, lagging behind the broader US market’s 10.5% annual growth rate. With profitability still out of reach in...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you...

Pet Valu Holdings (TSX:PET) reported a profit margin of 8.5%, up from 8% last year, with earnings growing at 11.6% in the most recent year. This outpaced its five-year average growth of 9.6% per year. Revenue and earnings are both expected to expand faster than the Canadian market, with forecasts of 6.9% and 15.2% annual growth respectively. Investors are likely to view these results, alongside improved margins and a current P/E ratio of 21.1x that sits below the peer group average, as...

Indraprastha Medical Corporation Limited ( NSE:INDRAMEDCO ) shareholders have had their patience rewarded with a 31...

LGI Homes (LGIH) reported a 20.4% annual decline in earnings over the past five years, with current net profit margins at 5.9% compared to 8.8% previously. However, revenue is projected to grow at 17.4% per year, while EPS is expected to jump by 27.4% annually for the next three years, outpacing the broader US market’s 16% outlook. With margins under recent pressure but robust growth prospects ahead, investors will be weighing risks from declining profitability against strong forward-looking...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Key Insights Institutions' substantial holdings in S.J.S. Enterprises implies that they have significant influence over...

To the annoyance of some shareholders, Jay Bee Laminations Limited ( NSE:JAYBEE ) shares are down a considerable 33% in...

Rhythm Pharmaceuticals (RYTM) reported widening losses, with net losses having grown at a rate of 18.8% per year over the past five years. Despite being unprofitable, the company commands a Price-To-Sales Ratio of 40x, outpacing both the US Biotechs industry average of 10.8x and the peer average of 17.9x, positioning its stock as highly valued on these multiples. On the growth front, forecasts point to revenue expanding at 45.8% per year and earnings projected to grow 70.56% per year, with...

ACC Limited ( NSE:ACC ) just released its latest second-quarter results and things are looking bullish. ACC delivered a...